Guidelines for Stability Testing of Gene Therapy Products as per FDA Guidelines
1) Purpose
The purpose of this Standard Operating Procedure (SOP) is to provide guidelines for conducting stability testing for gene therapy products in accordance with US FDA requirements. This SOP ensures that stability data supports the quality, safety, and efficacy of gene therapy products throughout their shelf life.
2) Scope
This SOP applies to all personnel involved in the design, execution, and documentation of stability studies for gene therapy products intended for the US market.
3) Responsibilities
Stability Testing Team: Responsible for conducting stability studies and documenting results for gene therapy products as per US FDA guidelines.
Quality Assurance (QA) Team: Responsible for reviewing and approving stability study protocols and reports.
Regulatory Affairs Team: Responsible for ensuring that stability studies meet the US FDA regulatory expectations for gene therapy products.
4) Procedure
4.1 Preparation 
4.1.1 Obtain and review the latest US FDA guidelines for stability testing of gene therapy products.
4.1.2 Develop a stability protocol specific to gene therapy products, including study design, testing schedule, storage conditions, and testing parameters as per FDA guidelines.
4.2 Selection of Batches and Samples
4.2.1 Select representative batches of the gene
4.2.2 Prepare sufficient samples to cover the entire study duration, considering the number of time points and tests to be conducted.
4.3 Defining Storage Conditions and Time Points
4.3.1 Define the storage conditions according to FDA guidelines, which may include refrigerated or frozen storage conditions depending on the product.
4.3.2 Establish the time points for sampling, such as 0, 3, 6, 9, 12, 18, and 24 months for long-term studies, and additional time points for accelerated studies.
4.4 Conducting Stability Tests
4.4.1 Store samples under the defined conditions, ensuring they are protected from conditions that could degrade their stability, such as exposure to light or temperature fluctuations.
4.4.2 At each specified time point, remove samples and conduct stability-indicating tests, including potency, purity, and biological activity tests, as applicable.
4.4.3 Record all results meticulously in stability data sheets, ensuring accuracy and traceability of data.
5) Abbreviations, if any
FDA: United States Food and Drug Administration
QA: Quality Assurance
6) Documents, if any
Stability protocol, stability data sheets, stability testing records, stability report, submission package to FDA.
7) Reference, if any
FDA Guidance for Industry: Stability Testing of Gene Therapy Products.
8) SOP Version
Version 1.0